{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-240890","form_type":"8-K","ticker":"HCWB","cik":"0001828673","company_name":"HCW Biologics Inc.","filed_at":"2025-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.658363+00:00","generated_at":"2026-05-17T03:35:27.473713+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nasdaq grants HCW Biologics extension to regain compliance by Dec 31, 2025","bullets":["Nasdaq Hearings Panel granted extension to demonstrate compliance with Equity Rule by Dec 31, 2025, and all listing rules by Feb 16, 2026.","Company was non-compliant with Listing Rule 5550(b)(1) (minimum stockholders' equity) as of June 30, 2025.","Hearing held September 25, 2025; Panel considered Company's compliance plan.","Company must timely file Form 10-Q for Q3 and notify Nasdaq of significant events during exception period.","Panel may review its decision within 45 calendar days after written decision."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-240890","json":"https://secwatch.observer/filing/0001193125-25-240890.json","markdown":"https://secwatch.observer/filing/0001193125-25-240890.md","text":"https://secwatch.observer/filing/0001193125-25-240890.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828673/000119312525240890/0001193125-25-240890-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828673/000119312525240890/hcwb-20251013.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:35:27.473713+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e7acf8be1ce1fdcca7720af1eecc1f6780aa6e8","claim":"HCW Biologics Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"October 13, 2025, the Panel granted the Company an extension in which to regain compliance with all continued listing rules of the Exchange. The Panel’s determination follows the Company’s hearing on September 25, 2025, at which the Company presented, and the Panel considered, the Company’s plan to regain compliance with the Equity Rule. The Panel granted the Company’s request for continued listing on the Exchange, subject to, among other things, the Company demonstrating compliance with the Equity Rule by December 31, 2025, and with all other Exchange continued listing rules by February 16, 2","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828673/000119312525240890/0001193125-25-240890-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}